Mosquirix, also known as RTS,S/AS01, is the first approved malaria vaccine aimed at protecting children from the life-threatening disease caused by the Plasmodium falciparum parasite. Developed by GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative and other stakeholders, Mosquirix has been endorsed by the World Health Organization (WHO) for use in regions with moderate to high transmission of malaria.
